

Innovations in the Risk Assessment of Low-Risk Active Substances of Botanical Origin for Crop Protection: AOPs, and NAMs

P. Barciela^{1,2}; E-N. Papadakis³; Z. Vryzas³; M. Carpena^{1,2}; M.A. Prieto^{1,2*}

¹ Universidade de Vigo, Nutrition and Food Group (NuFoG), Department of Analytical Chemistry and Food Science, Instituto de Agroecoloxía e Alimentación (IAA) – CITEVI, 36310 Vigo, Spain.

² Investigaciones Agroalimentarias Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO, Vigo, Spain; paula.barciela@uvigo.es; mprieto@uvigo.es

³ Pesticide Science Laboratory, Faculty of Agriculture Forestry and Natural Environment, School of Agriculture, Aristotle University of Thessaloniki, Greece; papadakm@agro.auth.gr

*Corresponding author: M.C. (mcarpena@uvigo.es); Z.V. (zvryzas@agro.auth.gr)

The 1st International Electronic Conference on Plant Protection — Science and Solutions for a Climate Crisis; 2–8 March 2026

Section 1: Background and rationale

- Regulatory basis:** Reg (EC) No. 1107/2009 allows **active substances (AS)** to qualify as **low-risk (LRs)**, promoting their use as alternatives to synthetic **plant protection products (PPPs)**.
- Limited uptake:** Despite this provision, botany-based **LRs** remain **undefined** in the EU system; **LRs** accounting for **<10%** of approvals, with **botanicals** being a **minor share**.
- Assessment challenge:** Although botanicals are biologically derived and expected to present lower risk profiles, their regulatory assessment **remains complex** and **data-intense**.
- Data requirements:** Botanical **LRs** are subject to the same toxicological data package as synthetic **AS** under Reg (EU) No. 283/2013 and 284/2013.
- Mismatch of testing frameworks:** The standard toxicological and ecotoxicological tests (OECD/EFSA) are often ill-suited to botanicals, which are chemically complex mixtures.
- Burden on applicants-data gaps:** This approach results in **high costs** and **lengthy timelines**, disproportionately affecting **botanical products** and **limiting innovation** and **market access**.

Section 2: Core definitions


a) LR of botanical origin: plant-derived **AS** used in **PPP** that meet the **low-approval criteria** of Reg (EC) No. 1107/2009 (Article 22; Annex II). They must be adequately characterized (e.g., **plant source**, **extract process**, **compositional markers**) and not be classified as carcinogenic, mutagenic, or toxic for reproduction (**CMR Cat. 1A/1B**) under Reg (EC) No 1272/2008 (**CLP**);

- not meet the criteria for **endocrine disruption**;
- not exhibit **neurotoxic** or **immunotoxic** properties;
- be **non-persistent** (soil $DT_{50} \leq 60$ days; water $DT_{50} \leq 40$ days);
- be **non-bioaccumulative** ($BCF \leq 100$);
- not cause **unacceptable effects on non-target organisms**

b) Adverse outcome pathways (AOPs): mechanistic frameworks recognized in **EU regulatory science** that describes a biologically plausible and causally linked sequence of key events, from a molecular initiating stage to an adverse outcome relevant for regulatory decision-making.

c) New Approach Methodologies (NAMs): sets of **non-animal and alternative testing** (*in vitro*, *in silico*, and mechanistic approaches) endorsed in **EU risk assessment (RA)** to generate data for hazard identification and characterization, support **mechanism-based decision-making**, and **enable the reduction of animal testing** (Figure 1).

Section 3: Methodology



Section 4: Results

The **multifaceted nature** of botanical extracts can lead to data gaps regulatory **bottlenecks**. Barriers to approval include perceived **toxicity**, **limited ecotoxicological data**, and the inability to apply **single-molecule hazard models**. Case studies comparing botanical and chemically derived **AS** reveal that adopting the full **synthetic-style dossier** for plant-based products hinders their approval and implementation. **AOP-informed** and **NAM-based strategies** effectively identify mechanistic hazards, refining **exposure** and risk characterization in line with **EFSA uncertainty** and **weight-of-evidence** principles to reduce reliance on vertebrate testing. **Figure 2** exemplifies the **decision-making process** for botanical **LRs** using **exposure-driven logic** to evaluate effective regulatory protection while eliminating unnecessary testing. These advances promote a **proportionate, predictive, ethics-aligned RA** process tailored to botanical **LRs**.

Section 5: Conclusions

Within the framework of **next-generation RA** for **PPP**, complementary approaches, such as the **Qualified Presumption of Safety (QPS)**, **AOPs**, **Weight-of-Evidence (WoE) assessment**, **read-across**, and **NAMs**, can be integrated to develop **fit-for-purpose RA** schemes for specific **LRs pesticides**, including **botanicals**. In this context, **AOPs** and **NAMs** were occupied to design a **tiered strategy** for **prioritizing testing** methods, enabling **faster** and more **cost-efficient** authorization of **botanical pesticides** while maintaining a **high level of safety**.

Acknowledgements

This work was supported by an **EFSA EU-FORA fellowship grant (EUBA-EFSA-2024-ENREL-01)**, which funds the **LowRiskPesticides** project and the work of **P. Barciela**. The scientific evaluations presented here do not necessarily reflect the views of EFSA.




Figure 1. Methods, tools, applications, and systems commonly encompassed under the umbrella of NAMs. Created in <https://BioRender.com>




Figure 2. AOP- and NAM-informed decision tree based on EFSA and OECD guidelines for the regulatory RA of LR botanical AS. Irregular hexagons = decision points; Rounded boxes = data/evidence; Dashed arrows = NAM-based refinement; Green = clearance; Red = risk management. Created in <https://BioRender.com>